PolyNovo Limited (ASX:PNV) CEO Paul Brennan presents at the ASX CEO Sessions in Sydney.PolyNovo
(ASX:PNV) develops unique, patented, biodegradable polymers for use in medical devices.
PolyNovo’s current focus is on developing and commercialising innovative medical devices using its NovoSorb technology in the treatment of burns, surgical wounds and Negative Pressure Wound Therapy.
Its current product is BTM (Biodegradable Temporising Matrix) – a wound dressing used to treat full-thickness wounds and burns where the dermal structure has been lost to trauma, or damaged requiring surgical removal, and requires a split-thickness skin graft for final closure.
BTM is used in five states of the US, with more to come on-stream in coming months. Initial surgeon experience with BTM has been positive, showing robust performance in challenging cases.
PolyNovo has an exclusive distribution agreement for BTM sales with Device Technologies in Australia and New Zealand.
In South Africa, Surgical Innocations is the company's exclusive distribution for BTM. Other distributor markets for potential entry in CY 2017 include Israel, India, Hong Kong and the Middle East.
